UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) ~~of the Securities Exchange Act of 1934~~

~~Date~~ of the ~~Report~~Securities ~~(date~~Exchange Act of ~~earliest event reported): April 26, 2022~~1934

~~ADORBS~~Date of ~~INC.~~Report (date of earliest event reported): March 13, 2023

SOUL BIOTECHNOLOGY CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Nevada		000-56213		82-3155323
(State of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

234 E. Beech St. Long Beach, New York		11561
36 Fourth Ave. N, Saskatchewan, Canada		S3N 2V7
(Address of principal executive offices)		(Zip Code)

(516) 544-2812

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered under Section 12(g) of the Exchange Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock ADOB N/A

Securities registered pursuant to Section 12(b) of the Act: None

~~Item~~Securities ~~4.01~~registered ~~Changes~~pursuant into ~~Registrant’s~~Section ~~Certifying~~12(g) ~~Accountant.~~of the Act:

On April 26, 2022, Adorbs Inc. (the “Company”) terminated its engagement with AJSH & Co LLP (“AJSH”), the Registrant’s prior independent registered public accounting firm, and thereafter provided AJSH with its disclosures in the Current Report on Form 8-K disclosing the termination of the engagement of AJSH and requested in writing that AJSH furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether or not they agree with such disclosures. AJSH's response is filed as an exhibit to this Current Report on Form 8-K.

Title of Each Class		Name of Each Exchange On Which Registered
Common Stock, $0.001 par value per share		N/A

~~The~~Item ~~auditor~~5.02 ~~reports~~Departure ~~by AJSH contained in the financial statements~~ of ~~the~~Directors ~~Company~~or ~~for~~Certain ~~the~~Officers; ~~years~~Election ~~ended December 31, 2021 and 2020, filed as part~~ of ~~the~~Directors; ~~annual~~Appointment ~~reports on Form 10-K for the years ended December 31, 2021 and 2020, did not contain an adverse opinion or disclaimer~~ of ~~opinion~~Certain orOfficers; ~~were~~Compensatory ~~qualified~~Arrangements or modified as to uncertainty, audit scope or accounting principles, other than to state that there is substantial doubt as to the Company’s ability to continue as a going concern. There had been no disagreements with AJSH on any matter of ~~accounting~~ ~~principles~~Certain ~~or practices, financial statement disclosure, or auditing scope or procedure during the fiscal years ended December 31, 2021 and 2020, nor in the subsequent periods through April 26, 2022~~Officers.

On ~~April~~March 2613, ~~2022~~2023, the ~~Board~~sole ofexisting ~~Directors~~director ofand ~~the~~officer ~~Company~~resigned ~~engaged~~immediately. BFAccordingly, ~~Borgers~~David ~~CPA~~Lazar, PCserving ~~(“Borgers”)~~ as ~~its~~a ~~independent~~director ~~accountant~~and an officer, ceased to ~~provide~~be ~~auditing~~the ~~services~~President, ~~for~~Chief ~~going~~Executive ~~forward~~Officer, ~~for~~Chief Financial Officer, and as a Member of the Board of Directors of the Company. Also ~~The~~on ~~Company~~March ~~has~~13, ~~terminated~~2023, Rachel Martinuik consented to the ~~engagement~~new CEO, CFO, Treasurer, and a Member of the Board of Directors of the Company ~~AJSH.~~and ~~The~~Nichol ~~decision~~Martinuik consented to ~~hire~~act ~~Borgers~~as ~~was~~the ~~approved~~new byPresident, ~~the~~Secretary, ~~Company’s~~and a Member of the Board of Directors of the Company.

~~Item~~Rachel Martinuik, 947, CEO and Chair of the board of MySpray, has been part of MySpray from inception.01 ~~Financial~~In ~~Statements~~her previous role as Chief Operating Officer, her responsibilities included the oversight of MySpray’s resources and ~~Exhibits~~oversees budgetary expenditures. A large part of her role was to build relationships with members of the supply chain, production labs, fulfillment, and logistic teams that all operate for MySpray remotely across Canada. Outside of MySpray, Rachel was appointed by the honorable Brad Wall to a board position for Saskatchewan Opportunities Corporation (SOCO), where she served three terms, from 2015-2021. SOCO operates under the registered business name of Innovation Place a Saskatchewan Crown Corporation. Innovation Place owns and operates technology parks adjacent to the province’s universities in Saskatoon and Regina, which provides a home for 3,800 tech jobs across 150 different companies in well over 1 million square feet of managed indoor space. In 2018 Rachel earned the ICD.D designation from the Institute of Corporate Directors. Rachel is a graduate from the University of Regina with a Bachelor of Human Justice. Her education in board management and social justice provides the awareness to keep the company mindful of the personal, corporate, and social responsibility we occupy.

Exhibit No.		Description
16.1		Letter dated May 5, 2022 from AJSH & Co LLP

Nichol Martinuik, 47, President & Founder of MySpray, has been in health sciences, traditional medicine, and the natural health industry since 1997, gaining clinical experience in pain management, disease prevention, and therapeutic health solutions. He is a seasoned doctor of natural medicine (homeopathy), registered massage therapist, and natural health researcher. Nichol is the President and Founder of MySpray Therapeutics Inc., and HMTC - Homeopathic Medical & Therapy Clinic, and is registered with the Natural Health Practitioners of Canada and the Saskatchewan Association of Doctors of Natural Medicine.

1Item 9.01 Financial Statements and Exhibits.

~~SIGNATURES~~(d) Exhibits.

~~Pursuant~~99.1 toDIRECTORS ~~the~~RESOLUTIONS, ~~requirements of~~dated ~~the~~March ~~Securities Exchange Act of 1934~~13, ~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized~~2023.

~~May 5, 2022~~1

~~Adorbs, Inc. /s/ David Lazar By: David Lazar Title: CEO~~SIGNATURES

2Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

March 13, 2023

SOUL BIOTECHNOLOGY CORPORATION

By:	/s/ Rachel Martinuik
Name:	Rachel Martinuik
Title:	CEO

Filing Compare · Adorbs Inc